부산대학교 도서관

Currently, three recombinant antigens based vaccines are under clinical trials against Schistosomiasis , but there is no vaccine available for prophylaxis or therapeutic. This study was conducted to construct a multi-epitope based vaccine against Schistosoma mansoni via utilizing Sm14, Sm21.7, Sm23, Sm29, Smp80, Sm-CB and SM-TSP-2 antigens. Helper T lymphocyte (HTL), cytotoxic T lymphocyte (CTL) and IFN-γ epitopes were predicted. Furthermore, Pan HLA DR-binding epitope was added to the vaccine. Moreover, 50S ribosomal protein L7/L12 of Mycobacterium tuberculosis as a novel TLR4 agonist was applied. The TAT peptide was added to the vaccine to augment intracellular delivery. The selected epitopes were linked together through appropriate linkers and chimeric vaccine was constructed with 617 amino acids with molecular weight of 65.43 kDa. Physico-chemical properties revealed a soluble protein with antigenic and non-allergic properties. Further analyses validated the stability of the construct that was able to interact with TLR4. Immunoinformatics analysis demonstrated the strong potential of constructed vaccine to stimulate T and B-cell mediated immune responses. In summary, obtained data indicated that the proposed vaccine can properly induce both T and B cells immune responses and could possibly be utilized for prophylactic or therapeutic aims in response to infection caused by S. mansoni. • There was no commercial vaccine for Schistosoma mansoni. • A CHIMERIC vaccine through immuno-informatic approaches was designed. • Sm14, Sm21.7, Sm23, Sm29, Smp80, and SM-TSP-2 antigens were applied in vaccine. • The construct showed strong potential to induce humoral and cellular immunity. • Dynamic simulation verified microscopic interaction between the vaccine and TLR4. [ABSTRACT FROM AUTHOR]